Tekmira Slumps 11% After an update on TKM-Ebola-Guinea Print
By Staff and Wire Reports   
Friday, 19 June 2015 15:26

Industry leading therapeutic solutions firm Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) has confirmed developing cure for hepatitis B virus infection which the Phase II clinical trial of TKM-Ebola-Guinea has achieved.

The endpoint demonstrated that the ongoing enrollment was unlikely to show an overall therapeutic benefit.

Data analysis is going on and complete results would be soon available. Dr. Peter Horby, Associate Professor of Infectious Diseases and Global Health, University of Oxford, Chief Investigator, opined that it is a tribute to the team in Sierra Leone that the trial went on smoothly and the firm has big experience on the use of TKM-Ebola-Guinea in patients having Ebola.

Horby added that the trial has entered an important stage and the last conclusions on the efficiency as well as tolerability of drug would have to wait for full analysis of data.

In the trial, TKM-Ebola-Guinea is evaluated for efficiency in Ebola virus infected patients in Sierra Leone, West Africa.

The Phase II single arm trial called RAPIDE (Rapid Assessment of Potential Interventions & Drugs for Ebola) is open-label with simultaneous observational study of Ebola virus disease in Sierra Leone.

The representative of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), The University of Oxford, is responsible for doing Phase II study, the money for which is given by Wellcome Trust.

The Ebola-Guinea strain is known as "Ebola virus Makona" which is known for current outbreak in West Africa.

This strain moves away from Kikwit strain that was original target of TKM-Ebola.

Genomic sequence of Ebola-Guinea strain was assessed from a number of viral isolates and published in New England Journal of Medicine in October 2014.

 The firm developed modified RNAi therapeutic depending on the firm’s original TKM-Ebola investigational therapeutic to mainly target Ebola-Guinea.

The new product that is known as TKM-Ebola-Guinea, is made for matching genomic sequence exactly with two RNAi triggers.

The capability of correctly matching evolving genetic sequences of emerging infectious agents is a powerful feature of RNAi therapeutics.

Shares of the company fell 11.60% to $13.28.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!